×
About 55,098 results

Roles of alpha-7 nicotinic acetylcholine receptors and spleen in the lung injury induce...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513867
BMC Pulmonary Medicine; Fatemikia H, Dehghanian A et. al.

Sep 28th, 2022 - The study aimed to determine whether or notα7 nicotinic acetylcholine receptors (α7nAChR) induce anti-inflammatory effects directly in the lung or through the spleen pathway in a sterile model of lung injury by saline lavage. Male Sprague Dawley rats were divided into seven groups; Sham, splenectomy (SPX), saline lavage (LAV), LAV treated with α7nAChR agonist nicotine (LAV + NIC), and LAV treat...

Drugs Used in Circadian Sleep-Wake Rhythm Disturbances.
https://doi.org/10.1016/j.jsmc.2022.06.007
Sleep Medicine Clinics; Burgess HJ, Emens JS

Sep 24th, 2022 - This article focuses on melatonin and other melatonin receptor agonists and summarizes their circadian phase shifting and sleep-enhancing properties, along with their associated possible safety concerns. The circadian system and circadian rhythm sleep-wake disorders are described, along with the latest American Academy of Sleep Medicine recommendations for the use of exogenous melatonin in trea...

Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
https://doi.org/10.1056/NEJMoa2200433
The New England Journal of Medicine; , Nathan DM et. al.

Sep 22nd, 2022 - The comparative effectiveness of glucose-lowering medications for use with metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain. In this trial involving participants with type 2 diabetes of less than 10 years' duration who were receiving metformin and had glycated hemoglobin levels of 6.8 to 8.5%, we compared the effectiveness of four commonly use...

A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizo...
https://doi.org/10.1097/JCP.0000000000001596
Journal of Clinical Psychopharmacology; Kane JM

Sep 14th, 2022 - This continuing education supplement is jointly provided by Medical Education Resources and CMEology. The supplement is supported by an independent educational grant from Sunovion Pharmaceuticals Inc. It was edited and peer reviewed by the Journal of Clinical Psychopharmacology.After reviewing the learning objectives and reading the supplement, please complete the Activity Evaluation/Credit Req...

Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Recept...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449794
JAMA Lamprea-Montealegre JA, Madden E et. al.

Sep 7th, 2022 - Novel therapies for type 2 diabetes can reduce the risk of cardiovascular disease and chronic kidney disease progression. The equitability of these agents' prescription across racial and ethnic groups has not been well-evaluated. To investigate differences in the prescription of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) among adu...

Selective TAAR1 agonists induce conditioned taste aversion.
https://doi.org/10.1007/s00213-022-06222-5
Psychopharmacology Liu J, Wu R et. al.

Sep 3rd, 2022 - Trace amine-associated receptor 1 (TAAR1) is the best-studied receptor of trace amines, a group of biogenic amines expressed at a relatively low level in the mammalian brain. Growing evidence suggests that TAAR1 plays a critical role in various neuropsychiatric disorders. Given that selective TAAR1 agonists were shown to produce pro-cognition and antipsychotic-like effects as well as to suppres...

A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzhei...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482428
Proceedings of the National Academy of Sciences of the Un... Ortí-Casañ N, Zuhorn IS et. al.

Aug 30th, 2022 - Tumor necrosis factor-α (TNF-α) is a pleiotropic, proinflammatory cytokine related to different neurodegenerative diseases, including Alzheimer's disease (AD). Although the linkage between increased TNF-α levels and AD is widely recognized, TNF-α-neutralizing therapies have failed to treat AD. Previous research has associated this with the antithetic functions of the two TNF receptors, TNF rece...

Group III metabotropic glutamate receptors as promising targets for neuroprotective the...
https://doi.org/10.1016/j.pbb.2022.173452
Pharmacology, Biochemistry, and Behavior; Domin H

Aug 29th, 2022 - There is still no effective treatment for central nervous system (CNS) pathologies, including cerebral ischemia, neurotrauma, and neurodegenerative diseases in which the Glu/GABA balance is disturbed with associated excitotoxicity. It is thus important to search for new efficacious therapeutic strategies. Preclinical studies on the role of metabotropic glutamate receptors (mGluRs) in neuroprote...

Anticancer efficacy of endo- and exogenous potent ligands acting at dopaminergic recept...
https://doi.org/10.1016/j.ejphar.2022.175230
European Journal of Pharmacology; Laskowska AK, Kleczkowska P

Aug 27th, 2022 - Cancer is one of the most common and dreaded diseases affecting the vastness of society. Unfortunately, still some people die especially when cancer is not diagnosed and thus caught early enough. On the other hand, using available chemo- or radiotherapy may result in serious side effects. Therefore, cancer-specific medications seem to be the most desired and safe therapy. Knowing that some canc...

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficac...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400320
Cardiovascular Diabetology; McGuire DK, D'Alessio D et. al.

Aug 25th, 2022 - Cardiovascular (CV) outcome trials (CVOTs) of type 2 diabetes mellitus (T2DM) therapies have mostly used randomized comparison with placebo to demonstrate non-inferiority to establish that the investigational drug does not increase CV risk. Recently, several glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter 2 inhibitors (SGLT-2i) demonstrated reduced CV risk....

Phosphorylation of muramyl peptides by NAGK is required for NOD2 activation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477735
Nature Stafford CA, Gassauer AM et. al.

Aug 25th, 2022 - Bacterial cell wall components provide various unique molecular structures that are detected by pattern recognition receptors (PRRs) of the innate immune system as non-self. Most bacterial species form a cell wall that consists of peptidoglycan (PGN), a polymeric structure comprising alternating amino sugars that form strands cross-linked by short peptides. Muramyl dipeptide (MDP) has been well...

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400295
Cardiovascular Diabetology; Baviera M, Foresta A et. al.

Aug 24th, 2022 - GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) have shown to reduce the risk of major adverse cardiovascular events (MACE), death and worsening nephropathy when added to standard of care. However, these two dug classes differ in efficacy and safety. We compared the effectiveness and safety profile of GLP-1 RA and SGLT-2i in a large and unselected cohort of patients with type...

C1-inhibitor influence on platelet activation by thrombin receptors agonists.
https://doi.org/10.1177/10760296221120422
Clinical and Applied Thrombosis/hemostasis : Official Jou... Tarandovskiy ID, Buehler PW et. al.

Aug 24th, 2022 - Protease activated receptors 1 (PAR1) and 4 (PAR4) agonists are used to study platelet activation. Data on platelet activation are extrapolated across experimental settings. C1-inhibitor (C1INH) is a protease inhibitor present in plasma but not in isolated platelet suspensions. Here we show that C1INH affects platelet activation through PAR1 and PAR4 agonists. Platelets were isolated from healt...

Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mou...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436334
Proceedings of the National Academy of Sciences of the Un... Evans R, Kimura H et. al.

Aug 23rd, 2022 - Narcolepsy type 1 (NT1) is a sleep disorder caused by a loss of orexinergic neurons. Narcolepsy type 2 (NT2) is heterogeneous; affected individuals typically have normal orexin levels. Following evaluation in mice, the effects of the orexin 2 receptor (OX2R)-selective agonist danavorexton were evaluated in single- and multiple-rising-dose studies in healthy adults, and in individuals with NT1 a...

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392232
Military Medical Research; Razavi M, Wei YY et. al.

Aug 20th, 2022 - Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food and Drug Administration (FDA) and some members of the scientific comm...

Incretin based therapy and pancreatic cancer: Realising the reality.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280733
World Journal of Gastroenterology; Suryadevara V, Roy A et. al.

Aug 19th, 2022 - Incretin-based therapies like glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help maintain the glycaemic control in patients with type 2 diabetes mellitus with additional systemic benefits and little risk of hypoglycaemia. These medications are associated with low-grade chronic pancreatitis in animal models inconsistently. The incidence of acute pancreatitis was...

Comparative genomic analysis of five freshwater cyanophages and reference-guided metage...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382816
Microbiome Du K, Yang F et. al.

Aug 17th, 2022 - As important producers using photosynthesis on Earth, cyanobacteria contribute to the oxygenation of atmosphere and the primary production of biosphere. However, due to the eutrophication of urban waterbodies and global warming, uncontrollable growth of cyanobacteria usually leads to the seasonal outbreak of cyanobacterial blooms. Cyanophages, a group of viruses that specifically infect and lys...

Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Trans...
https://doi.org/10.1016/j.amjcard.2022.07.012
The American Journal of Cardiology; Lopez PD, Bhatia K et. al.

Aug 14th, 2022 - Sodium-glucose co-transporter 2 inhibitors (SGLT2i) reduce the risk of cardiovascular events and heart failure hospitalization (HFH) in patients with heart failure with reduced ejection fraction (HFrEF), diabetes mellitus type 2 (DM2), and atherosclerotic cardiovascular disease (ASCVD). The role of glucagon-like peptide 1 agonists (GLP1a) in these patients is unclear. We designed this study to ...

Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepati...
https://doi.org/10.1016/j.antiviral.2022.105386
Antiviral Research; Desmares M, Delphin M et. al.

Aug 14th, 2022 - Pegylated-interferon-alpha (Peg-IFNα), an injectable innate immune protein, is still used to treat chronically HBV-infected patients, despite its poor tolerability. Peg-IFNα has the advantage over nucleos(t)ide analogues (NAs) to be administrated in finite regimen and to lead to a higher HBsAg loss rate. Yet it would be interesting to improve the efficacy (i.e. while decreasing doses), or repla...

2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and S...
https://doi.org/10.1016/j.cjca.2022.04.029
The Canadian Journal of Cardiology; Mancini GBJ, O'Meara E et. al.

Aug 13th, 2022 - This guideline synthesizes clinical trial data supporting the role of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of heart failure (HF), chronic kidney disease, and for optimizing prevention of cardiorenal morbidity and mortality in patients with type 2 diabetes. It is on the basis of a companion systematic review and meta-anal...